[Alteration of survivin gene expression in ovarian cancer cell line CAOV3 after chemotherapy in vitro].
OBJECTIVE
To study the alteration of survivin gene expression in ovarian cancer cell CAOV3 after chemotherapy in vitro.


METHODS
After the secondary culture of ovarian cancer cell line CAOV3, inhibition of ovarian cancer cell growth induced by paclitaxel or carboplatin at different concentration was detected by methyl thiazolyl tetrazolium (MTT). Alteration of survivin mRNA expression was evaluated by reverse transcription polymerase chain reaction (RT-PCR) in ovarian cancer cells which had been cultured with paclitaxel or carboplatin of high concentration (200, 500 mg/L) for 1 d or of low concentration (20, 50 mg/L) for 1, 3 and 5 d, respectively. Meanwhile, CAOV3 cell apoptosis was detected by flow cytometry.


RESULTS
The inhibition rates on growth of ovarian cancer cell CAOV3 by different concentrations of paclitaxel or carboplatin after 48 h were 94%, 88%, 34%, 22%, 13% and 97%, 46%, 14%, 9%, 7%. The apoptosis rates of CAOV3 in low concentration paclitaxel for 1, 3, and 5 d were 15%, 23% and 29%. And the apoptosis rate in high concentration paclitaxel for 1 d was 43%. The apoptosis rate of CAOV3 in low concentration carboplatin for 1, 3, and 5 d were 14%, 22% and 26%. And in high concentration carboplatin for 1 d the rate was 19%. Expression of survivin mRNA increased distinctly after culturing in paclitaxel or carboplatin of low concentration for 3 d and of high concentration for 1 d compared to the control group (P < 0.01), the increase was especially evident in paclitaxel treated group (P < 0.01).


CONCLUSIONS
Survivin gene may play an inhibitory role in the chemotherapy of ovarian cancer cell CAOV3 in vitro.
Zhang
Shu-Lan
SL
Department of Obstetrics and Gynecology, the Second Affiliated Hospital, China Medical University, Shenyang 110004, China.
Jiang
Tao
T
Lin
Bei
B
Zhao
Chang-Qing
CQ
Meng
Li-Rong
LR
D000970:Antineoplastic Agents / Q000494:pharmacology; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D014408:Biomarkers, Tumor; D016190:Carboplatin / Q000494:pharmacology*; D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins / Q000096:biosynthesis* / Q000235:genetics; D009363:Neoplasm Proteins / Q000096:biosynthesis* / Q000235:genetics; D010051:Ovarian Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D017239:Paclitaxel / Q000494:pharmacology*; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D000077022:Survivin
D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; C107489:BIRC5 protein, human; D014408:Biomarkers, Tumor; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D012333:RNA, Messenger; D000077022:Survivin; D016190:Carboplatin; D017239:Paclitaxel